Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- BINV.ST
- Price
- 27.10
- Stock movement up
- +0.15 (0.56%)
- Company name
- BioInvent International AB
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.78B
- Ent value
- 1.15B
- Price/Sales
- 46.16
- Price/Book
- 1.78
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 2.78
- PEG
- -
- EPS growth
- -10.80%
- 1 year return
- 47.12%
- 3 year return
- -17.58%
- 5 year return
- -5.78%
- 10 year return
- -5.22%
Last updated: 2025-04-15
DIVIDENDS
BINV.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 46.16 |
| Price to Book | 1.78 |
| EV to Sales | 29.77 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 65.80M |
| EPS (TTM) | -6.23 |
| FCF per share (TTM) | -5.58 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 38.64M |
| Gross profit (TTM) | 38.64M |
| Operating income (TTM) | -456.77M |
| Net income (TTM) | -409.65M |
| EPS (TTM) | -6.23 |
| EPS (1y forward) | 9.74 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 100.00% |
| Operating margin (TTM) | -1182.23% |
| Profit margin (TTM) | -1060.29% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 717.36M |
| Net receivables | 50.98M |
| Total current assets | 1.01B |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 47.42M |
| Total assets | 1.09B |
| Accounts payable | 67.36M |
| Short/Current long term debt | 17.02M |
| Total current liabilities | 76.06M |
| Total liabilities | 84.38M |
| Shareholder's equity | 1.00B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -354.55M |
| Capital expenditures (TTM) | 11.94M |
| Free cash flow (TTM) | -366.49M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -40.84% |
| Return on Assets | -37.67% |
| Return on Invested Capital | -40.49% |
| Cash Return on Invested Capital | -36.22% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 27.00 |
| Daily high | 27.30 |
| Daily low | 26.40 |
| Daily Volume | 49K |
| All-time high | 965.32 |
| 1y analyst estimate | 90.00 |
| Beta | 0.38 |
| EPS (TTM) | -6.23 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 22 Apr 2025 |
Downside potential
Loading...
Downside potential data
| BINV.ST | S&P500 | |
| Current price drop from All-time high | -97.19% | -12.04% |
| Highest price drop | -98.54% | -56.47% |
| Date of highest drop | 1 Nov 2023 | 9 Mar 2009 |
| Avg drop from high | -80.26% | -11.07% |
| Avg time to new high | 2961 days | 12 days |
| Max time to new high | 5920 days | 1805 days |
COMPANY DETAILS
Marketcap
1.78B
Marketcap category
Small-cap
Description
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to treat solid tumors targeting FCYRIIB; and BT-001 in phase 1 clinical trial for the treatment of solid tumors targeting Cytotoxic T lymphocyte-associated protein-4. The company has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BI-1206, BI-1808, and BT-001 in combination with Keytruda; and licensing agreement with CASI pharmaceuticals for BI-1206. The company was incorporated in 1996 and is based in Lund, Sweden.
Employees
115
Website
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
LUND, SWEDEN / ACCESS Newswire / April 8, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class...
April 8, 2025
LUND, SE / ACCESS Newswire / April 4, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class imm...
April 4, 2025
LUND, SE / ACCESS Newswire / April 1, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class im...
April 1, 2025
LUND, SE / ACCESS Newswire / March 25, 2025 /BioInvent International (STO:BINV) The shareholders of BioInvent International AB (publ), Reg. No 556537-7263, are hereby invited to attend the Annual Gene...
March 25, 2025
LUND, SE / ACCESS Newswire / March 21, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class i...
March 21, 2025
LUND, SE / ACCESS Newswire / March 20, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class im...
March 20, 2025
LUND, SWEDEN / ACCESS Newswire / February 27, 2025 / BioInvent International (STO:BINV) "2024 was a year with several exciting developments reported from across our broad portfolio of clinical program...
February 27, 2025
LUND, SE / ACCESS Newswire / February 25, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) invites investors, analysts, and the press to a presentation of the Year-end report 202...
February 25, 2025
LUND, SWEDEN / ACCESSWIRE / January 10, 2025 / BioInvent International (STO:BINV) BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and deve...
January 10, 2025
LUND, SWEDEN / ACCESSWIRE / January 8, 2025 / BioInvent International (STO:BINV) The first two patients enrolled in the Phase 2a study triplet arm combining BI-1206 with rituximab and Calquence® respo...
January 8, 2025
Next page